Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

A federal judge in West Virginia denied Regeneron's request for an injunction against Amgen's Pavblu, creating uncertainty around Eylea's U.S. market exclusivity. At the time, Leerink's Risinger ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) from a market perform rating to an outperform rating in a research report released on Wednesday ...

Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable options, 2 are puts, totaling $104,155, and 14 are calls, amounting to $721 ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

today announced that the Company will present at the Leerink Global Healthcare Conference being held in Miami, FL on Tuesday, March 11, 2025 at 10:00 a.m. ET. A live webcast of the presentation ...

In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...